Evidence map›Paper›PMID 36838818›Full record

ArticleMolecules (Basel, Switzerland)2023

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers.

Fengqin Yan, Zhenfu Fu, Guo Li, Zhiguo Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Fengqin YanDepartment of Radiotherapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.
Zhenfu FuDepartment of Radiotherapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.
Guo LiDepartment of Biochemistry and Molecular Biology, Hainan Medical University, Haikou 571199, China.ORCID 0000-0002-2634-3955
Zhiguo WangInstitute of Ageing Research, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China.ORCID 0000-0001-8732-4451
Zhejiang Cancer Hospital · CNHainan Medical University · CNHangzhou Normal University · CN

Funding

Hainan Provincial Key Research and Development Program ZDYF2022SHFZ308National Natural Science Foundation of China 32160161Natural Science Foundation of Hainan Province 822MS075Wu Jieping Medical Foundation 320.6750.2021-01-28Zhejiang Provincial Natural Science Foundation of China LY18H250002
6 · The paper itself

Abstract

The protein PARP1, which plays a crucial role in DNA repair processes, is an attractive target for cancer therapy, especially for BRCA-deficient cancers. To overcome the acquired drug resistance of PARP1,

Indexed as

G-QuadruplexesNeoplasmsDNA RepairHumansPhthalazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPARP1 protein, humanPhthalazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsBRCA deficiencymolecular dynamicsmolecular mechanismPARP1 G-quadruplexPARP1 inhibition

Identifiers

PMID36838818
PMCPMC9961911
OpenAlexW4320918329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.